We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+50.06%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$383M
AUM Growth
+$107M
Cap. Flow
+$27.1M
Cap. Flow %
7.08%
Top 10 Hldgs %
52.27%
Holding
53
New
13
Increased
10
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$22.8M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$18.1M
3
BPMC
Blueprint Medicines
BPMC
+$17.7M
4
SAGE
Sage Therapeutics
SAGE
+$10.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.83M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$17M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$13.4M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$11.9M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$7.64M
5
OBSV
ObsEva SA Ordinary Shares
OBSV
+$4.52M

Sector Composition

Rank Sector Weight
1 Healthcare 84.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
51
PUT
DELISTED
Immunomedics Inc
IMMU
– –
-800,000
Closed -$11.4M
BDSI
52
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-1,000,000
Closed -$3.7M
BHVN
53
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-275,000
Closed -$11.9M
1 2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Ghost Tree Capital held 53 positions worth $383M, up 39% from $276M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Ghost Tree Capital deployed $27.1M of net new capital in Q1 2019, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was Blueprint Medicines: 240,000 shares worth $19.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 61% a quarter earlier.

On the sell side, the largest reduction was Mirati Therapeutics, Inc. Common Stock, an estimated $17M trimmed.

  • Ghost Tree Capital's largest Q1 2019 buy was Blueprint Medicines: 240,000 shares worth $19.2M.
  • Ghost Tree Capital added most to Ascendis Pharma A/S in Q1 2019, an estimated $22.8M increase.
  • Ghost Tree Capital's biggest Q1 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $17M.
  • Ghost Tree Capital fully exited Dicerna Pharmaceuticals, Inc. in Q1 2019, selling an estimated $13.4M.
  • Ghost Tree Capital's ten largest holdings make up 52% of its $383M portfolio in Q1 2019.
  • Ghost Tree Capital opened 13 new positions and closed 14 in Q1 2019.
  • Ghost Tree Capital's portfolio value rose 39% quarter-over-quarter to $383M.

Based on Ghost Tree Capital's 13F filing for Q1 2019, filed 15 May 2019.